Market Research Report
Diabetic Retinopathy Market Size By Type, By Age Group, By Management, By Distribution Channel, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 - 2025
|Published by||Global Market Insights Inc.||Product code||605740|
|Published||Content info||120 Pages
Delivery time: 2-3 business days
|Diabetic Retinopathy Market Size By Type, By Age Group, By Management, By Distribution Channel, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 - 2025|
|Published: April 18, 2019||Content info: 120 Pages||
Diabetic Retinopathy Market Size By Type (Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy), By Age Group (40-49, 50-64, 65-74), By Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Distribution Channel (Hospitals & Pharmacies, Eye Clinics, Ambulatory Surgical Centers (ASCs)), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Japan, India, China, Australia, South Korea, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE), Application Potential, Competitive Market Share & Forecast, 2019 - 2025.
Rising prevalence of diabetes in developed as well as developing economies will positively influence the industry growth. According to WHO, people diagnosed with diabetes increased to 422 million in 2014. Diabetes has associated complications and most frequent amongst them is diabetic retinopathy. As per Hindawi Journal of Ophthalmology, 80% patients suffering from diabetes for more than 20 years have the tendency to acquire diabetic retinopathy. This scenario favors diabetic retinopathy market growth as it increases the demand for medications and ophthalmic surgical procedures.
Improvements in medications available for diabetic retinopathy treatment will foster the industry growth. Recently developed direct injections, intravitreal antiangiogenesis and anti-inflammatory agents are prominently used to treat diabetic retinopathy that has helped in retaining vision. Therefore, advances in medications and procedures have revolutionized the treatment for diabetic retinopathy thereby, escalating the industry growth. However, certain surgical procedures available for treatment of diabetic retinopathy may lead to post-surgical complications that may restrain the industry growth to some extent.
Proliferative diabetic retinopathy segment is predicted to witness 7.5% growth throughout the forecast time period. This type of condition is highly severe as it is most advanced phase of diabetic eye diseases and surgical procedures are crucial for improving vision. According to data of Apollo Hospitals, people above 60 years have the highest probability of acquiring proliferative diabetic retinopathy that should propel the segmental growth.
40-49 age group of diabetic retinopathy segment was valued around 3 billion in 2018. Vigorous segmental growth will be as a result of increasing prevalence of diabetic patients in this group. People in the age group of 40-49 consists of working professional that have unhealthy lifestyle such as lack of exercise and consumption of junk food that makes them susceptible to chronic diseases such as diabetes. According to NCBI article, patients suffering from diabetes have 30% probability of acquiring diabetic retinopathy. Thus, increasing prevalence of diabetes in age group of 40-49 should augment segmental growth.
Laser surgery segment will grow at 9.2% over the analysis period owing to shorter recovery period associated with it. Additionally, laser surgeries are minimally invasive, thus making the treatment less painful. Therefore, preference for minimally invasive surgeries is high in geriatric population that drives the segment growth. Furthermore, less post-surgical complications associated with laser surgery will positively influence the segment growth.
Ambulatory surgical centers (ASCs) segment was valued over 2 billion in 2018 and is expected to witness enormous growth over forecast timeframe. Diabetic retinopathy treatments are most probably performed on outpatient basis. Outpatient surgical procedure costs are comparatively less as the recovery period is short. Moreover, ophthalmic procedures performed at ASCs are reimbursed that increases its preference amongst people in developing economies facing affordability issues. Above mentioned factors are expected to drive the business growth.
North America diabetic retinopathy market was valued at USD 3 billion in 2018. Increasing geriatric population suffering from chronic conditions including diabetes will drive the regional industry growth. Elderly population base suffering from diabetes have the highest probability of acquiring diabetic retinopathy, that will lead to high demand for advanced medications in this region. Moreover, increasing awareness regarding availability of minimally invasive ophthalmic surgeries in North America has positively impacted the industry growth.
Prominent industry players operational in the diabetic retinopathy market include Regeneron Pharmaceuticals, BCN Peptides, Kowa Company, Allergan and Bayer AG, Novartis, Ampio Pharmaceuticals, ThromboGenics and Alimera Sciences. Key players adopt strategies such as mergers and acquisitions, emphasis on R&D and new product launch. Approval for product launch from regulatory bodies from FDA has positive impact on company's sales. For instance, in September 2014, Allergan announced approval of OZURDEX in the European Union for the treatment of Diabetic Macular Edema. Receiving FDA approval for newly developed products will boost company's growth.